✦ LIBER ✦

Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the children's oncology group (COG)

✍ Scribed by Malogolowkin, Marcio H.; Krailo, Mark; Marina, Neyssa; Olson, Thomas; Frazier, A. Lindsay

Book ID: 120706949
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 90 KB
Volume: 60
Category: Article
ISSN: 1545-5009
DOI: 10.1002/pbc.24601

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Amifostine does not protect against the

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors : A children's oncology group study

✍ Neyssa Marina; Kay W. Chang; Marcio Malogolowkin; Wendy B. London; A. Lindsay Fr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

High-dose chemotherapy and blood stem ce

High-dose chemotherapy and blood stem cell autografts for children with first relapsed acute lymphoblastic leukemia: A pilot study of the children's cancer and leukemia study group of Japan (CCLSG)

✍ Takaue, Yoichi ;Watanabe, Arata ;Murakami, Tatsuo ;Watanabe, Tsutomu ;Kawano, Yo 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

## Abstract This study was performed to determine the value of high‐dose chemotherapy and peripheral blood stem cell autografts (PBSCT) in the treatment of children with first relapsed acute lymphoblastic leukemia (ALL). Eighteen children underwent PBSCT during the second complete remission (CR) an

A Phase I study of granulocyte-macrophag

A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors : A report of the Children's Cancer Group

✍ Mitchell S. Cairo; Mark D. Krailo; Joel A. Weinthal; Rita Secola; Sharon Bergero 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 3 views

## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a